SELLAS Life Sciences Group, Inc. financial data

Symbol
SLS on Nasdaq
Location
7 Times Square, Suite 2503, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 308 % +280%
Debt-to-equity 42.8 % -99.4%
Return On Assets -92.8 % +63.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 105M shares +63.7%
Common Stock, Shares, Outstanding 100M shares +73.8%
Entity Public Float 68.6M USD +54.4%
Common Stock, Value, Issued 10K USD +100%
Weighted Average Number of Shares Outstanding, Basic 98.6M shares +71%
Weighted Average Number of Shares Outstanding, Diluted 98.6M shares +71%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Costs and Expenses 27.2M USD -21.9%
Operating Income (Loss) -27.2M USD +21.9%
Nonoperating Income (Expense) 924K USD +153%
Net Income (Loss) Attributable to Parent -26.3M USD +23.8%
Earnings Per Share, Basic 0 USD/shares +66.7%
Earnings Per Share, Diluted 0 USD/shares +66.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.3M USD +177%
Assets, Current 29.4M USD +139%
Operating Lease, Right-of-Use Asset 683K USD +7.9%
Goodwill 1.91M USD 0%
Assets 32.3M USD +114%
Accounts Payable, Current 3.34M USD -47.3%
Employee-related Liabilities, Current 1.04M USD -40.3%
Accrued Liabilities, Current 2.08M USD -59.8%
Liabilities, Current 6M USD -50.2%
Operating Lease, Liability, Noncurrent 157K USD -2.48%
Liabilities 6.16M USD -49.6%
Retained Earnings (Accumulated Deficit) -261M USD -11.2%
Stockholders' Equity Attributable to Parent 26.1M USD +798%
Liabilities and Equity 32.3M USD +114%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.07M USD +15.7%
Net Cash Provided by (Used in) Financing Activities 23.6M USD -11.5%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 100M shares +73.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5M USD -8.65%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.4M USD +175%
Deferred Tax Assets, Valuation Allowance 20.9M USD +11%
Deferred Tax Assets, Gross 21.1M USD +10.9%
Operating Lease, Liability 737K USD +6.5%
Lessee, Operating Lease, Liability, to be Paid 794K USD +6.58%
Operating Lease, Liability, Current 580K USD +9.23%
Lessee, Operating Lease, Liability, to be Paid, Year Two 477K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 477K USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 57K USD +7.55%
Deferred Tax Assets, Operating Loss Carryforwards 14.1M USD +15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 700K USD +40%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 200K USD +8.7%
Share-based Payment Arrangement, Expense 1.76M USD -4.87%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%